Abstract Number: 1910 • 2012 ACR/ARHP Annual Meeting
Regulation of Microrna 223 Expression in a Gouty Arthritis
Background/Purpose: Gout is an inflammatory chronic disease caused by deposition of uric acid crystals in the joint and connective tissues causing pain and disability. Current…Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…Abstract Number: 1913 • 2012 ACR/ARHP Annual Meeting
Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase that acts via enzymatic degradation of uric acid to allantoin, is approved in the US for the treatment…Abstract Number: 1914 • 2012 ACR/ARHP Annual Meeting
The Diagnosis and Management of Gout in 2012: Survey of US and Canadian Rheumatologists
Background/Purpose: The introduction of novel treatment modalities for gout has escalated interest and education on this topic. Although gout is the most common inflammatory arthropathy…Abstract Number: 1915 • 2012 ACR/ARHP Annual Meeting
Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients
Background/Purpose: Hyperhomocysteinemia, which is related with cardiovascular diseases and metabolic syndrome, is regarded as one of the important factors in endothelial cell damage processes. It…Abstract Number: 1916 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout
Background/Purpose: Using data pooled from the randomized, placebo-controlled trials (RCTs) of pegloticase, post-hoc analyses of urate-lowering, antibody titers and the patterns of infusion-related reactions (IRs)…Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…Abstract Number: 1813 • 2012 ACR/ARHP Annual Meeting
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Background/Purpose: Gout outcome studies have used administrative and claims databases. It is unknown whether administrative-derived data are accurate for gout-related utilization. The goal of the…Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…Abstract Number: 1815 • 2012 ACR/ARHP Annual Meeting
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Background/Purpose: Management of gout in the hospital setting has been poor. This study aimed to describe patient characteristics and the treatment patterns of acute gout…Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…Abstract Number: 1661 • 2012 ACR/ARHP Annual Meeting
CCR1 Potentiates Gouty Inflammation Following Initial CXCR2-Dependent Neutrophil Recruitment to Sites of Monosodium Urate Crystal Deposition in Mice
Background/Purpose: During attacks of acute gouty arthritis, monosodium urate (MSU) crystals elicit a potent neutrophilic inflammatory response in the affected joint, causing exquisite pain and…Abstract Number: 1628 • 2012 ACR/ARHP Annual Meeting
Epistatic Interaction Between Solute Carrier 2A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk
Background/Purpose: Consumption of drinks sweetened with sugar or high fructose corn syrup increases both serum urate levels and the risk for gout. SLC2A9 encodes a…Abstract Number: 1629 • 2012 ACR/ARHP Annual Meeting
Microarray Analysis of Acute and Intercritical Gout
Background/Purpose: We aimed to identify the immune mechanism underlying gouty inflammation using microarrays analysis and modular gene expression signatures. Methods: Whole blood along with clinical…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »